Adhera Therapeutics, Inc. announces management changes, effective June 15, 2020
June 11, 2020 at 04:53 pm EDT
Share
Adhera Therapeutics, Inc. announced that on June 8, 2020, Nancy R. Phelan has resigned as an officer and as a member of the Board of Directors of the company (including, without limitation, Secretary of the company), and as an officer and as a member of the Board of Directors of any and all subsidiaries of the company, to pursue other professional opportunities. The foregoing resignations will be effective at the close of business on June 15, 2020.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
